References
Sacral neuromodulation system for treating refractory overactive bladder
Abstract
Sacral neuromodulation (SNM) is a therapy system used to improve bladder function, including in people with overactive bladder (OAB). It is safe and can improve quality of life. SNM helps improve symptoms through direct modulation of nerve activity; it involves electrically stimulating the sacral nerves that carry signals between the pelvic floor, spinal cord and the brain and is thought to normalise neural communication between the bladder and brain. If patients with OAB do not respond to non-surgical and conservative options, minimally invasive procedures can be offered, including SNM. SNM is performed in two stages: the trial phase, to assess whether it would be effective in the long term; and permanent implantation. This year, the National Institute for Health and Care Excellence (NICE) released guidance on the Axonics SNM System® for treating refractory OAB. The Axonics System is rechargeable and lasts at least 15 years, minimising the need for repeat surgery. NICE suggests the Axonics System may have cost advantages for the NHS. Having more than one SNM therapy option available increases options for patients, offering them a choice of handsets and rechargeable versus non-rechargeable implants. Three case studies illustrate how the system works in practice.
Sacral neuromodulation (SNM), also known as sacral neurostimulation, is a therapy used to help improve bladder and bowel function. It is one of the treatment options for overactive bladder (OAB) and has been proven to significantly improve quality of life (Benson et al, 2020).
Throughout the UK, bladder problems including OAB are common but are often not discussed. Bladder problems may be related to other medical conditions and can affect anyone at any stage of life (Bladder and Bowel UK, 2019). Most people do not access primary care services with bladder problems because they feel nothing can be done, plus it is a difficult subject to speak about or embarrassing.
SNM therapy received a CE mark for urinary dysfunction in 1994 and around 325 000 patients worldwide have been treated with it (Blok et al, 2020). SNM has been undertaken at Salford Royal NHS Foundation Trust since 1999, with the first permanent implantation procedure performed in early 2000. The trust has been carrying out this procedure longer than most units in the world.
Register now to continue reading
Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to clinical or professional articles
-
Unlimited access to the latest news, blogs and video content